Episode Ep 20 October 6, 2026 10 min 49s

Guideline Updates G20: IDSA 2024 AMR Guidance: Treating ESBL, CRE, CRAB, and DTR-Pseudomonas

From AZense Guideline Updates Azense Medical Education

The living IDSA guidance retires piperacillin-tazobactam for serious ESBL disease, makes ceftazidime-avibactam standard for KPC-type CRE, prefers sulbactam-durlobactam for CRAB, and requires novel agents for DTR-Pseudomonas

Community discussion

Join the conversation

Guideline Updates G20: IDSA 2024 AMR Guidance: Treating ESBL, CRE, CRAB, and DTR-Pseudomonas

You May Also Like

BIRNABEATZ

SmoothJazz.com Global

Voices from the Field

Teneki

Worship & Wonder Daily Devotional

NGN Radio

Book Friends Forever

Scrolls & Secrets

Lumin

Faith Outreach